TScan rolls out retention plan with $822,000 cash award for CEO Gavin MacBeath
TCRX•TScan sets cash-and-equity compensation package for top executives
TScan Therapeutics set a cash-and-equity compensation package for CEO Gavin MacBeath and Chief Legal and Strategy Officer Zoran Zdraveski.
- Cash awards total $822,000 for MacBeath and $416,000 for Zdraveski; first-half payments are split between November 2026 and February 2027.
- Second-half cash payments hinge on milestones tied to advancing the in vivo solid tumor program.
- Equity awards call for 2,400,000 RSUs for MacBeath and 1,050,000 RSUs for Zdraveski under the 2021 plan.
- One-third of RSUs vest on a financing milestone; the remaining two-thirds vest on the first two anniversaries, subject to continued service.
